REFERENCES
2. Dandona P, Dhindsa S. Update: hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab. 2011;96:2643-51.
3. Fuster JJ, Ouchi N, Gokce N, Walsh K. Obesity-induced changes in adipose tissue microenvironment and their impact on cardiovascular disease. Circ Res. 2016;118:1786-807.
4. Sbraccia P, D’Adamo M, Guglielmi V. Is type 2 diabetes an adiposity-based metabolic disease? From the origin of insulin resistance to the concept of dysfunctional adipose tissue. Eat Weight Disord. 2021;26:2429-41.
5. Powell-Wiley TM, Poirier P, Burke LE, et al. ; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and cardiovascular disease: a scientific statement from the American heart association. Circulation. 2021;143:e984-e1010.
6. Jiang Z, Wang Y, Zhao X, et al. Obesity and chronic kidney disease. Am J Physiol Endocrinol Metab. 2023;324:E24-41.
8. Thornberry NA, Bull HG, Calaycay JR, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992;356:768-74.
9. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in muckle-wells autoinflammatory disorder. Immunity. 2004;20:319-25.
10. Burnstock G, Verkhratsky A. Evolutionary origins of the purinergic signalling system. Acta Physiol (Oxf). 2009;195:415-47.
11. Di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S. The P2X7 receptor in infection and inflammation. Immunity. 2017;47:15-31.
13. Di Virgilio F, Vuerich M. Purinergic signaling in the immune system. Auton Neurosci. 2015;191:117-23.
14. Di Virgilio F, Sarti AC, Coutinho-Silva R. Purinergic signaling, DAMPs, and inflammation. Am J Physiol Cell Physiol. 2020;318:C832-5.
15. Ferrari D, Pizzirani C, Adinolfi E, et al. The P2X7 receptor: a key player in IL-1 processing and release. J Immunol. 2006;176:3877-83.
17. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93:359-404.
18. Chouchani ET, Kajimura S. Metabolic adaptation and maladaptation in adipose tissue. Nat Metab. 2019;1:189-200.
19. Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022;55:31-55.
20. Wu H, Ballantyne CM. Metabolic Inflammation and insulin resistance in obesity. Circ Res. 2020;126:1549-64.
21. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022;19:593-606.
22. D'Agati VD, Chagnac A, de Vries AP, et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol. 2016;12:453-71.
23. Rossato M, Favaretto F, Granzotto M, et al. Molecular and pharmacological evidence for the expression of multiple functional P2 purinergic receptors in human adipocytes. Molecules. 2022;27:1913.
24. Wang D, Zhou J. Purinergic receptor: a crucial regulator of adipose tissue functions. Purinerg Signal. 2023;19:273-81.
25. Caruso V, Zuccarini M, Di Iorio P, Muhammad I, Ronci M. Metabolic changes induced by purinergic signaling: role in food intake. Front Pharmacol. 2021;12:655989.
26. Panupinthu N, Rogers JT, Zhao L, et al. P2X7 receptors on osteoblasts couple to production of lysophosphatidic acid: a signaling axis promoting osteogenesis. J Cell Biol. 2008;181:859-71.
27. Giacovazzo G, Apolloni S, Coccurello R. Loss of P2X7 receptor function dampens whole body energy expenditure and fatty acid oxidation. Purinerg Signal. 2018;14:299-305.
28. Tian T, Heine M, Evangelakos I, et al. The P2X7 ion channel is dispensable for energy and metabolic homeostasis of white and brown adipose tissues. Purinerg Signal. 2020;16:529-42.
29. Burnstock G, Gentile D. The involvement of purinergic signalling in obesity. Purinerg Signal. 2018;14:97-108.
30. Madec S, Rossi C, Chiarugi M, et al. Adipocyte P2X7 receptors expression: a role in modulating inflammatory response in subjects with metabolic syndrome? Atherosclerosis. 2011;219:552-8.
31. Giuliani AL, Berchan M, Sanz JM, et al. The P2X7 receptor is shed into circulation: correlation with c-reactive protein levels. Front Immunol. 2019;10:793.
32. Di Vincenzo A, Granzotto M, Graziani A, et al. Soluble P2X7 receptor plasma levels in obese subjects before and after weight loss via bariatric surgery. Int J Mol Sci. 2023;24:16741.
33. Stienstra R, van Diepen JA, Tack CJ, et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci U S A. 2011;108:15324-9.
34. de Torre-Minguela C, Barberà-Cremades M, Gómez AI, Martín-Sánchez F, Pelegrín P. Macrophage activation and polarization modify P2X7 receptor secretome influencing the inflammatory process. Sci Rep. 2016;6:22586.
35. Beaucage KL, Xiao A, Pollmann SI, et al. Loss of P2X7 nucleotide receptor function leads to abnormal fat distribution in mice. Purinerg Signal. 2014;10:291-304.
36. Di Vincenzo A, Granzotto M, Crescenzi M, Vettor R, Rossato M. Non-aromatizable androgens modulate the lipopolysaccharide induced expression of the P2X7 receptor in human adipocytes. Front Pharmacol. 2023;14:1251035.
37. Escobar-Morreale HF, Santacruz E, Luque-Ramírez M, Botella Carretero JI. Prevalence of 'obesity-associated gonadal dysfunction’ in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis. Hum Reprod Update. 2017;23:390-408.
38. Becher T, Palanisamy S, Kramer DJ, et al. Brown adipose tissue is associated with cardiometabolic health. Nat Med. 2021;27:58-65.
39. O’Mara AE, Johnson JW, Linderman JD, et al. Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity. J Clin Invest. 2020;130:2209-19.
40. Coccurello R, Volonté C. P2X7 Receptor in the management of energy homeostasis: implications for obesity, dyslipidemia, and insulin resistance. Front Endocrinol (Lausanne). 2020;11:199.
41. Adinolfi E, Callegari MG, Ferrari D, et al. Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell. 2005;16:3260-72.
42. Giacovazzo G, Fabbrizio P, Apolloni S, Coccurello R, Volonté C. Stimulation of P2X7 enhances whole body energy metabolism in mice. Front Cell Neurosci. 2019;13:390.
43. Orioli E, De Marchi E, Giuliani AL, Adinolfi E. P2X7 Receptor orchestrates multiple signalling pathways triggering inflammation, autophagy and metabolic/trophic responses. Curr Med Chem. 2017;24:2261-75.
44. Chiang CH, Cheng CY, Lien YT, Huang KC, Lin WW. P2X7 Activation enhances lipid accumulation during adipocytes differentiation through suppressing the expression of sirtuin-3, sirtuin-5, and browning genes. Front Pharmacol. 2022;13:852858.
45. Okla M, Zaher W, Alfayez M, Chung S. Inhibitory Effects of toll-like receptor 4, NLRP3 inflammasome, and interleukin-1β on white adipocyte browning. Inflammation. 2018;41:626-42.
46. Jaeckstein MY, Fischer AW, Rissiek B, et al. Purinergic adipocyte-macrophage crosstalk promotes degeneration of thermogenic brown adipose tissue. EMBO Rep. 2025;26:6460-93.
47. Soehnlein O, Lutgens E, Döring Y. Distinct inflammatory pathways shape atherosclerosis in different vascular beds. Eur Heart J. 2025;46:3261-72.
48. Rossi C, Santini E, Chiarugi M, et al. The complex P2X7 receptor/inflammasome in perivascular fat tissue of heavy smokers. Eur J Clin Investig. 2014;44:295-302.
49. Ji X, Naito Y, Hirokawa G, et al. P2X(7) receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertens Res. 2012;35:173-9.
50. Ridker PM, Everett BM, Thuren T, et al. ; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-31.
51. Lombardi M, Mantione ME, Baccellieri D, et al. P2X7 receptor antagonism modulates IL-1β and MMP9 in human atherosclerotic vessels. Sci Rep. 2017;7:4872.
52. Piscopiello M, Sessa M, Anzalone N, et al. P2X7 receptor is expressed in human vessels and might play a role in atherosclerosis. Int J Cardiol. 2013;168:2863-6.
53. Bracey NA, Gershkovich B, Chun J, et al. Mitochondrial NLRP3 protein induces reactive oxygen species to promote Smad protein signaling and fibrosis independent from the inflammasome. J Biol Chem. 2014;289:19571-84.
54. Bracey NA, Beck PL, Muruve DA, et al. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1β. Exp Physiol. 2013;98:462-72.
55. Luo B, Li B, Wang W, et al. NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS ONE. 2014;9:e104771.
56. Ye T, Zhou Y, Yang J, et al. P2X7 receptor inhibition prevents atrial fibrillation in rodent models of depression. Europace. 2024;26:euae022.
57. Ye T, Yang J, Liu Z, et al. Inhibition of the P2X7 receptor prevents atrial proarrhythmic remodeling in experimental post-operative atrial fibrillation. Int Immunopharmacol. 2024;129:111536.
58. Yin J, Wang Y, Hu H, et al. P2X(7) receptor inhibition attenuated sympathetic nerve sprouting after myocardial infarction via the NLRP3/IL-1β pathway. J Cell Mol Med. 2017;21:2695-710.
59. Sun Y, Ma X, Gong Y, et al. Inhibition of P2X7R by hypericin improves diabetic cardiac autonomic neuropathy through the proteasome- Nrf2 - GPX4 signaling axis. Neurotoxicology. 2025;109:1-10.
60. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116:991-1006.
61. Choi JW, Lee CM, Kang BK, Kim M. Perirenal fat thickness is an independent predictor for metabolic syndrome in steatotic liver disease. Sci Rep. 2024;14:26548.
62. Menzies RI, Booth JWR, Mullins JJ, et al. Hyperglycemia-induced Renal P2X7 receptor activation enhances diabetes-related injury. EBioMedicine. 2017;19:73-83.
63. Menzies RI, Tam FW, Unwin RJ, Bailey MA. Purinergic signaling in kidney disease. Kidney Int. 2017;91:315-23.
64. Franco M, Bautista-Pérez R, Cano-Martínez A, et al. Physiopathological implications of P2X1 and P2X7 receptors in regulation of glomerular hemodynamics in angiotensin II-induced hypertension. Am J Physiol Renal Physiol. 2017;313:F9-F19.
65. Pandit MM, Inscho EW, Zhang S, et al. Flow regulation of endothelin-1 production in the inner medullary collecting duct. Am J Physiol Renal Physiol. 2015;308:F541-52.
66. Mounieb F, Abdel-Sattar SA, Balah A, Akool ES. P2 X 7 receptor is a critical regulator of extracellular ATP-induced profibrotic genes expression in rat kidney: implication of transforming growth factor-β/Smad signaling pathway. Purinerg Signal. 2024;20:421-30.
67. Menzies RI, Howarth AR, Unwin RJ, Tam FW, Mullins JJ, Bailey MA. Inhibition of the purinergic P2X7 receptor improves renal perfusion in angiotensin-II-infused rats. Kidney Int. 2015;88:1079-87.
68. Solini A, Menini S, Rossi C, et al. The purinergic 2X7 receptor participates in renal inflammation and injury induced by high-fat diet: possible role of NLRP3 inflammasome activation. J Pathol. 2013;231:342-53.
69. Yan Y, Bai J, Zhou X, et al. P2X7 receptor inhibition protects against ischemic acute kidney injury in mice. Am J Physiol Cell Physiol. 2015;308:C463-72.
70. Pereira JMS, Barreira AL, Gomes CR, et al. Brilliant blue G, a P2X7 receptor antagonist, attenuates early phase of renal inflammation, interstitial fibrosis and is associated with renal cell proliferation in ureteral obstruction in rats. BMC Nephrol. 2020;21:206.
71. Rodrigues AM, Serralha RS, Lima DY, et al. P2X7 siRNA targeted to the kidneys increases klotho and delays the progression of experimental diabetic nephropathy. Purinerg Signal. 2020;16:175-85.
72. Nespoux J, Monaghan MT, Jones NK, et al. P2X7 receptor knockout does not alter renal function or prevent angiotensin II-induced kidney injury in F344 rats. Sci Rep. 2024;14:9573.
73. Zhang R, Su K, Yang L, et al. Discovery of a potent, orally active, and long-lasting P2X7 receptor antagonist as a preclinical candidate for delaying the progression of chronic kidney disease. J Med Chem. 2024;67:17472-96.
74. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202-9.
75. Stefan N, Yki-Järvinen H, Neuschwander-Tetri BA. Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol. 2025;13:134-48.
76. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341-50.
77. Al-Hamoudi W, Alsadoon A, Hassanian M, et al. Endothelial dysfunction in nonalcoholic steatohepatitis with low cardiac disease risk. Sci Rep. 2020;10:8825.
78. Tarantino G, Costantini S, Finelli C, et al. Carotid intima-media thickness is predicted by combined eotaxin levels and severity of hepatic steatosis at ultrasonography in obese patients with nonalcoholic fatty liver disease. PLoS ONE. 2014;9:e105610.
79. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67:829-46.
80. Sanyal AJ, Newsome PN, Kliers I, et al. ; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089-99.
81. Verrastro O, Panunzi S, Castagneto-Gissey L, et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet. 2023;401:1786-97.
82. Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497-509.
83. Mladenić K, Lenartić M, Marinović S, Polić B, Wensveen FM. The “Domino effect” in MASLD: the inflammatory cascade of steatohepatitis. Eur J Immunol. 2024;54:e2149641.
84. Velázquez-Miranda E, Díaz-Muñoz M, Vázquez-Cuevas FG. Purinergic signaling in hepatic disease. Purinerg Signal. 2019;15:477-89.
85. Lu D, Insel PA. Cellular mechanisms of tissue fibrosis. 6. Purinergic signaling and response in fibroblasts and tissue fibrosis. Am J Physiol Cell Physiol. 2014;306:C779-88.
86. Hoque R, Sohail MA, Salhanick S, et al. P2X7 receptor-mediated purinergic signaling promotes liver injury in acetaminophen hepatotoxicity in mice. Am J Physiol Gastrointest Liver Physiol. 2012;302:G1171-9.
87. Savio LEB, de Andrade Mello P, Figliuolo VR, et al. CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury. J Hepatol. 2017;67:716-26.
88. Rossato M, Di Vincenzo A, Pagano C, El Hadi H, Vettor R. The P2X7 receptor and NLRP3 axis in non-alcoholic fatty liver disease: a brief review. Cells. 2020;9:1047.
89. Gaul S, Leszczynska A, Alegre F, et al. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis. J Hepatol. 2021;74:156-67.
90. Petrasek J, Bala S, Csak T, et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest. 2012;122:3476-89.
91. He K, Zhu X, Liu Y, et al. Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development. Oncotarget. 2017;8:37657-72.
92. Jiang S, Zhang Y, Zheng JH, et al. Potentiation of hepatic stellate cell activation by extracellular ATP is dependent on P2X7R-mediated NLRP3 inflammasome activation. Pharmacol Res. 2017;117:82-93.
93. Huang C, Yu W, Cui H, et al. P2X7 blockade attenuates mouse liver fibrosis. Mol Med Rep. 2014;9:57-62.
94. Huang H, Chen HW, Evankovich J, et al. Histones activate the NLRP3 inflammasome in Kupffer cells during sterile inflammatory liver injury. J Immunol. 2013;191:2665-79.
95. Wu T, Zhang C, Shao T, Chen J, Chen D. The role of NLRP3 inflammasome activation pathway of hepatic macrophages in liver ischemia-reperfusion injury. Front Immunol. 2022;13:905423.
96. Mridha AR, Wree A, Robertson AAB, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. 2017;66:1037-46.
97. Baeza-Raja B, Goodyear A, Liu X, et al. Pharmacological inhibition of P2RX7 ameliorates liver injury by reducing inflammation and fibrosis. PLoS ONE. 2020;15:e0234038.
98. Blasetti Fantauzzi C, Menini S, Iacobini C, et al. Deficiency of the purinergic receptor 2X(7) attenuates nonalcoholic steatohepatitis induced by high-fat diet: possible role of the NLRP3 inflammasome. Oxid Med Cell Longev. 2017;2017:8962458.
99. Dong Z, Wei Y, Tao M, Zhang L. Activation of the purinergic receptor P2X7 improves hepatosteatosis by promoting lipophagy. FEBS Lett. 2021;595:2768-80.
100. Arguin G, Bourzac JF, Placet M, et al. The loss of P2X7 receptor expression leads to increase intestinal glucose transit and hepatic steatosis. Sci Rep. 2017;7:12917.
101. Chandrashekaran V, Das S, Seth RK, et al. Purinergic receptor X7 mediates leptin induced GLUT4 function in stellate cells in nonalcoholic steatohepatitis. Biochim Biophys Acta. 2016;1862:32-45.
102. Povero D, Lazic M, McBride C, et al. Pharmacology of a potent and novel inhibitor of the NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome that attenuates development of nonalcoholic steatohepatitis and liver fibrosis. J Pharmacol Exp Ther. 2023;386:242-58.
103. Xiang L, Wang G, Zhuang Y, et al. Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study. J Hepatol. 2025;82:967-78.
104. Chatterjee S, Das S. P2X7 receptor as a key player in oxidative stress-driven cell fate in nonalcoholic steatohepatitis. Oxid Med Cell Longev. 2015;2015:172493.
105. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625-38.
107. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 2011;11:886-95.
108. Lengyel E, Makowski L, DiGiovanni J, Kolonin MG. Cancer as a matter of fat: the crosstalk between adipose tissue and tumors. Trends Cancer. 2018;4:374-84.
109. Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clin Invest. 2011;121:2094-101.
111. Di Virgilio F, Sarti AC, Falzoni S, De Marchi E, Adinolfi E. Extracellular ATP and P2 Purinerg Signal in the tumour microenvironment. Nat Rev Cancer. 2018;18:601-18.
112. Giannuzzo A, Saccomano M, Napp J, Ellegaard M, Alves F, Novak I. Targeting of the P2X7 receptor in pancreatic cancer and stellate cells. Int J Cancer. 2016;139:2540-52.
113. Brisson L, Chadet S, Lopez-Charcas O, et al. P2X7 receptor promotes mouse mammary cancer cell invasiveness and tumour progression, and is a target for anticancer treatment. Cancers (Basel). 2020;12:2342.
114. Shokoples BG, Paradis P, Schiffrin EL. P2X7 receptors: an untapped target for the management of cardiovascular disease. Arterioscler, Thromb, Vasc Biol. 2021;41:186-99.
115. Clinical Trial Arena Home Page. Available from: https://www.clinicaltrialsarena.com. (accessed 21 January 2026).
116. Muskiet MHA, Smits MM. Beyond a singular focus on GLP-1: why we need a new nomenclature now. Lancet Diabetes Endocrinol. 2025;13:730-3.
117. Ventrx bioscience Home Page. Available from: https://ir.ventyxbio.com. (accessed 21 January 2026).
